development of ion ampliseq community panels falcon global consortia nathalie bernard, market...
TRANSCRIPT
Development of Ion AmpliSeq™ Community PanelsFALCON Global Consortia
Nathalie Bernard, Market Development Manager, Inherited Disease
Ion AmpliSeq™ Community Panels
FALCON Leadership Consortia
Your workflow with your own content
Clinical Research Verification
Enabled by Life through leadership networks
Sign in to share your work with your peers
Check what is available on the Ion Community
Colon & lung
CFTR - panel
Cardio Genes panel
‘In this consortia we are sharing knowledge, technology, this is the main point’, Dr. Scarpa, University of Verona
BRCA1 and
BRCA2
BRCA1 and BRCA2 Global [email protected]
Prof. Jeffrey N. Weitzel Division of Clinical Cancer GeneticsCity of Hope Cancer Center. Los Angeles
Prof. Harriet Feilotter Department of Pathology at Queen's University. Ontario Canada
Dr. Alfredo Hidalgo Miranda, National Institute of Genomic Medicine. Mexico City, Mexico
Dr. Nicola Williams Southern General HospitalGlasgow
Dr. Jose Louis Costa andDr Jose Carlos MachadoIPATIMUP Medical Faculty of Porto. Portugal
Marjolijn J.L. Ligtenberg, Arjen R. MensenkampRadboud University NijmegenMedical Centre, The Netherlands
Dr. Arif B. Ekici Institute of Human GeneticsFriedrich-Alexander-University of Erlangen-Nürnberg
BRCA1 and BRCA2 Global Consortium
Goal: Develop a BRCA1 and BRCA2 NGS panel with Ion AmpliSeq™ technology and Ion PGM™ Sequencer 1. Coverage of targets:
– 100% coverage of all coding exons and exon-intron boundaries (-20 to +20)– Amplicons covering exons are overlapping
2. European Molecular Genetics Quality Network Guidelines– Primers do not overlap– No validated SNPs in the last five nucleotides of primer– Max 3 validated SNPs per primer
3. Adoptable by other research labs - accurate, affordable & easy – Single day workflow– Multiplex at least 6 samples per chip (316)– Reliable and easy data analysis – Ion Reporter ™ Software
Ion AmpliSeq™ BRCA1 & BRCA2 Panel
Resulting design meets requirements
– 167 amplicons across 3 primer pools (30 ng of DNA)– 200 bp design (single exception 349 bp)
• FFPE samples with lower performance– No SNP in the 3’ end of the primer– EMQN Best Practices Guidelines
“Care must be taken when designing PCR primers to avoid sequence variants (e.g. SNPs) in primer binding sites that could result in allele-
biased amplification”
European Molecular Genetics Quality Network
Ion AmpliSeq™ BRCA1 & BRCA2 PanelProject Design
• Design following collaborators’ requirements• First analytical verification on 20 archived samples• 9-mer homopolymer variants and MLPA variants
Phase 1:Design and test
• 30 archived samples with 65 known different variants tested and exchanged across 2 labs:
•Homopolymer stretches ✓•Deletions/insertions ✓•Point mutations ✓•Exon deletions ✓
• Multiplex 8 samples per Ion 316™ Chip
Phase 2:Analytical verification
and reproducibilityPanel launch
• Global verification will be performed in 8 labs on additional 200 archived samples with known variant status
Phase 3:Global consortium
verification
Ion AmpliSeq™ BRCA1 & BRCA2 Panel50 archived samples verified at Nijmegen and IPATIMUP
• Design following collaborators’ requirements• First analytical verification on 20 samples• 9-mer homopolymer variants and MLPA variants
Phase 1:Design and test
• 30 archived samples with 65 known different variants tested and exchanged across 2 labs:
•Homopolymer stretches ✓•Deletions/insertions ✓•Point mutations ✓•Exon deletions ✓
• Multiplex 8 samples per Ion 316™ Chip
Phase 2:Analytical verification
and reproducibilityPanel launch
• Global verification will be performed in 8 labs on additional 200 archived samples with known variant status
Phase 3:Global consortium
verification
✓
Ion AmpliSeq™ BRCA1 & BRCA2 PanelMetrics
– Average coverage uniformity: 98.8%– Average on-target specificity: 97.4%
http://ioncommunity.lifetechnologies.com/docs/DOC-7184
Sample 1 Sample 20.00%
20.00%40.00%60.00%80.00%
100.00%
On-target Specificity
Sample 1 Sample 20.00%
40.00%
80.00%
Coverage Uni-formity
Ion AmpliSeq™ BRCA1 & BRCA2 PanelProject Design
• Design following collaborators’ requirements• First analytical verification on 20 samples• 9-mer homopolymer variants and MLPA variants
Phase 1:Design and test
• 30 samples with 65 known different variants tested and exchanged across 2 labs:
•Homopolymer stretches ✓•Deletions/insertions ✓•Point mutations ✓•Exon deletions ✓
• Multiplex 8 samples per Ion 316™ Chip
Phase 2:Analytical verification
and reproducibilityPanel launch
• Global verification will be performed in 8 labs on additional 200 samples with known variant status
• Ion Reporter Analysis workflow Optimization
Phase 3:Global consortium
verification
✓
✓
Bioinformatics pipeline
• Trim adapter sequences
• Remove poor signal reads
• Split reads per barcode
• Assembly • Allignment
• Coverage Analysis• SNP/Indel
Detection• Annotate Variants
• Identify pathogenic variants
• Identify known polymorphisms
• Verify variants found• Extract Report
Read Generation Read Mapping
Variant Calling and Variant Annotation
Variant confirmation
and Interpretive
Report
Ion Reporter™ Software
Report
FilterAnalyze
Ion Reporter pre-configured
workflow
Ion Reporter™ Software Review Richly Annotated Variant list
>
Analyze
>
Sequence Import
BRCA 1 and BRCA2 Global ConsortiumPreliminary Results from five labs (Phase 3 verification)
• Data: Nijmegen – Porto – Erlangen – Glasgow – Canada• Analysis: Ion Reporter™ pre-configured BRCA Workflow
• Workflow contains modified parameters for calling homopolymers• Not including in the sensitivity the samples with large exon deletions
Type of Mutation Unique Mutations Samples Sensitivity
In long homopolymer 11 12/12 100%
Indel 61 67/67 100%
point mutations 51 55/55 100%
123 134/134 100%
Ion Reporter™ Software
Example of FP detection rate in one lab
Ion Reporter™ SoftwareBRCA1/2 single sample workflow
TP FP Sensitivity PPV
Run1 (10 samples) 109 3 100% 97.32%
Run2 (10 samples) 75 5 100% 96.15%
Run3 (10 samples) 55 3 100% 94.8%
Run4 (10 samples) 67 2 100% 97%
Coverage Analysis per Lab Across Runs
10
100
1000
10000
100000
lab1lab2lab3lab4lab5
Amplicon in exon 23 of BRCA2
Take home message: Minimum coverage 100x. However, amplicon in exon 23 of BRCA2 might exhibit low coverage ( >~60x) in some runs. Even in that case, variants can be detected in this exon in this region with the current workflow in Ion Reporter™
Coverage of Amplicon in Exon 23 - BRCA2 Gene within the labs
• Most of the runs in all the labs have coverage over 100x for this amplicon• Low coverage is run-specific.• Even low coverage ( > 60x), variants can be detected in this exon in this
region with the current workflow in Ion Reporter™
Low high-throughput runrun1 run2 run3 run4
10
100
1000
10000
100000
lab1lab2lab3lab4lab5
Ion AmpliSeq™ BRCA1 & BRCA2 Panel303-bp deletion in IGV
• 303-bp deletion beyond scope of panel design and variant caller• Heterozygous deletion initially detected by MLPA• Deletion can be observed from coverage
Molecular subsets of lung and colon adenocarcinoma
Pao & Hutchinson et al. Nature 2012
OncoNetwork [email protected]
Dr. Nicola NormannoCentro Ricerche Oncologiche
Mercogliano, Italy
Prof. Orla SheilsTrinity College Dublin, Ireland
Dr. Marjolijn Ligtenberg & Dr. Bastiaan TopsRadboud University
Nijmegen Medical CentreThe Netherlands
Prof. Ian CreeWarwick Medical School United Kingdom
Prof. Pierre Laurent PuigUniversité Paris Descartes, France
Dr. Ludovic LacroixInstitut Gustave Roussy Paris, France
Prof. Aldo ScarpaARC-NET University of Verona,
Italy
Dr. Cristoph Noppen & Dr. Henriette Kurth
VIOLLIER AG Basel, Switzerland
8 labs experienced in colon & lung cancer research
OncoNetwork Consortium
Goal: Develop a colon and lung tumor NGS panel with Ion AmpliSeq™ technology and Ion PGM™ Sequencer
22 selective gene content for colon and lung cancer research Markers in the receptor tyrosine kinase (RTK) pathway Include genes that might serve in the near future, AKT1, DDR2 and ERBB2 Selection of the genes regions based on mutation frequencies
Use low amount of input DNA Single primer pool requiring only 10 ng of DNA
Adoptable by other research labs Verified on archived FFPE samples Single day workflow Easy data analysis – Ion Reporter ™ Software
Ion AmpliSeq™ Colon and Lung Cancer PanelPanel design and relevance
– New genes DDR2 and MEK1– KRAS exon4 to include codons 117 to 146– EGFR exon12 to include codon 492– BRAF exon11 to include codons 466 and 469
22 genes – 90 Amplicons- more than 500 variantsReceptor Tyrosine Kinases
genes EGFR, ERBB2, ERBB4, MET, FGFR1, FGFR2, FGFR3, DDR2, ALK
Receptor tyrosine kinases Pathway Genes KRAS, NRAS ,PIK3CA, BRAF, PTEN, MAP2K1, AKT1
Cancer-related genes TP53, STK11, CTNNB1, SMAD4, FBXW7, NOTCH1
Verification Workplan 155 archived FFPE Samples by 7 laboratories
• Same 5 FFPE control samples across 7 labs• 2 KRAS AcroMetrix® cell line controls, 1 lung tumor research
sample, 2 xenograft colon tumor research sample
Phase 1:Reproducibility
Accuracy
• 10 FFPE blind samples, 6 labs, 60 samples total• 10 colon and lung tumor FFPE research samples• Each lab sent in 10 previously tested samples & received back
10 blind samples for sequencing
Phase 2:Concordance
• 15 FFPE samples, 6 labs 90 samples total• Each lab sequences 10 lung & 5 colon tumor research
samples• Samples vary greatly in tumor content levels
(heterogeneity)
Phase 3:Analytical Sensitivity
Ion AmpliSeq™ Colon and Lung Cancer Panel v1Amplicon Coverage
Sensitivity too low Loss of chip capacity
Ion AmpliSeq™ Colon and Lung Cancer Panel v2Amplicon Coverage
Further optimization of primer set
More equal coverage, novel verification
8 instead of 5 samples on Ion 316 ™ chip
Verification Workplan 89 archived FFPE samples Ion AmpliSeq™ Colon and Lung Cancer Panel v2
• Same 7 control FFPE samples across 7 labs• 2 KRAS AcroMetrix® cell line controls, 2 xenograft
colon , 3 lung tumor research samples
Phase 1:Reproducibility and Accuracy
• 10 blind FFPE samples across 6 labs, 60 samples total
• 10 colon and lung tumor research • Each lab sent in 10 previously tested samples &
received back 10 blind samples for sequencing
Phase 2:Concordance
• 15 FFPE samples in 5 labs, 75 samples total• Each lab sequences 10 lung & 5 colon tumor research
samples• Samples vary greatly in tumor content levels
(heterogeneity)
Phase 3:Analytical Sensitivity
Phase 1: Ion AmpliSeq™ Colon and Lung Cancer Panel v2100% Reproducibility - 7 FFPE samples - 7 labs Ion Reporter ™ Software
FFPE Sample type
Gene Protein lab1 lab2 lab3 lab4 lab5 lab6 lab7
1- Xenograft PIK3CA E542K ✓ ✓ ✓ ✓ ✓ ✓ ✓
1- Xenograft KRAS G12D ✓ ✓ ✓ ✓ ✓ ✓ ✓
1- Xenograft TP53 G244D ✓ ✓ ✓ ✓ ✓ ✓ ✓
2- Xenograft PIK3CA E545K ✓ ✓ ✓ ✓ ✓ ✓ ✓
2- Xenograft KRAS G12D ✓ ✓ ✓ ✓ ✓ ✓ ✓
2- Xenograft FBXW7 R465H ✓ ✓ ✓ ✓ ✓ ✓ ✓
1- Lung KRAS G12C ✓ ✓ ✓ ✓ ✓ ✓ ✓
1- AcroMetrix® KRAS G13D ✓ ✓ ✓ ✓ ✓ ✓ ✓
2- AcroMetrix® KRAS G12A ✓ ✓ ✓ ✓ ✓ ✓ ✓
W5 EGFR Deletion 19 ✓ ✓ ✓ ✓ ✓ ✓ ✓
W3 EGFR L858R ✓ ✓ ✓ ✓ ✓ ✓ ✓
Phase 3: Ion AmpliSeq™ Colon and Lung Cancer Panel v2 100% Genotyping Sensitivity - 75 FFPE difficult samples
** Lab 3 tested three different samples with the new panel with three different new mutations which were correctly detected
KRAS EGFR BRAF TP53 PTEN STK11 ERBB2Expected Variants
FOUND Detection
Rate %
Lab 1SNVs 6 3 2 - - - - 11 ✓
100
Indel - 1 - 1 - - - 2 ✓
LAB 2 SNVs 5 1 - - - - - 6 ✓
100
indel - 2 - - - - - 2 ✓
LAB 3 SNVs 6 2 3 - - - - 11 ✓
100
indel - 5 - - - - 1 4 ✓
LAB 4 SNVs 2 2 - - - - - 4 ✓
100
indel - 2 - - - - - 2 ✓
LAB 5 SNVs 6 1 (dupl) 2 - 1 1 - 11 ✓
100
indel - - - - - - - - ✓
The major classes of genomic alterations that give rise to cancer
Modified from McConaill - JCO 2010
EGFRErbB-2BRAFPIK3CAAKT1MAP2K1 EML4-ALK
ROS-1RET
EGFRErbB-2MET
Sequencing,Real Time PCR etc.
FISH,Immunohistochemistry
OncoNetwork Global Consortium
Prof. Harriet Feilotter Department of Pathology at Queen's University. Ontario Canada
Dr. Jose CostaIPATIMUP Medical Faculty of Porto. Portugal
Marjolijn J.L. Ligtenberg, Arjen R. Mensenkamp
Radboud University NijmegenMedical Centre, The Netherlands
Dr. Nicola NormannoCentro Ricerche
Oncologiche Mercogliano, Italy
Prof. Orla SheilsTrinity College Dublin, Ireland
Prof. Ian CreeWarwick Medical School United Kingdom
Prof. Pierre Laurent PuigUniversité Paris Descartes, France
Dr. Ludovic LacroixInstitut Gustave Roussy Paris, France
Prof. Aldo ScarpaARC-NET University of
Verona Italy
Dr. Cristoph Noppen & Dr. Henriette KurthVIOLLIER AG Basel,
Switzerland
Prof. Kazuto Nishio, M.D. Kinki University School of Medicine, Osaka, Japan
Cecily P. Vaughn ARUP Institute for Clinical and Experimental Pathology
Ion AmpliSeq™ Colon and Lung Panel – [email protected]
Goal: Redesign the Ion AmpliSeq™ Colon and Lung panel to include new biomarkers and copy number detection
Include the same gene targets of the colon and lung panel Add NRAS exon 4 variants ( p.117, p.146) and more ALK variants Add Copy number detection for the genes MET, FGFR1 ,FGFR2, ERBB2, MEK1, EGFR, ALK,
KRAS, PTEN . Do not change the primers design of the existing amplicons
Use low amount of input DNA Single primer pool requiring only 10 ng of DNA
Adoptable by other research labs Verified on archived FFPE samples Single day workflow Easy data analysis – Ion Reporter ™ Software
Lung Fusion Panel
Goal: Develop a lung tumor fusion panel based on Ion AmpliSeq™ RNA technology
1. Selective gene content related to Lung tumor Covers fusion variants of ALK, ROS and RET genes.
2. Use low amount of input RNA Single primer pool requiring only 10 ng of RNA
3. Internal positive control included Use ALK, ROS, RET gene expression targets
4. Panel Verified by the Consortium on FFPE archived samples: 200+ FFPE archived samples previously tested by FISH, ICH or qPCR for EML/ALK fusions High selection of positive samples from archived samples.
5. Adoptable by other research labs Single day workflow Multiplex at least 8 samples per Ion 316™ chip Reliable and easy data analysis Provide the same level of information as FISH
FALCON Global Consortia ProcessIon Community™ Panels
Develop applications that satisfy customer needs Content and workflow defined by International Consortia
Analytical verification part of the development process Panel tested on clinical research samples at collaborator’s lab
Complete workflow including software solution Include collaborators need to use the panel in their settings
Share experiences of it with other users Be part of a community
Ion AmpliSeq™ Portfolio Positioning
Design
Verification
Kits in inventory?
Life Technologies Customer Community
Life Technologies Customer Community
Yes, ready-to-useMade-to-order via
ampliseq.comMade-to-order via
ampliseq.com
Colon and Lung PanelBRCA1 - BRCA2 Panel
CFTR PanelTP53 Panel
AML Genes PanelCardio Genes Panel
Lung Fusion RNA PanelColon and lung Panel new design
Ion AmpliSeq™ Community Panels Design RoadmapHuman Genetics and Cancer Research focus
CFTR Global [email protected]
Prof. Peter RaySick Kids Hospital, Toronto Ontario Canada
Prof. Claude FerecLGMH – CHU BrestBrest, France
Prof. Martin SomervilleAlberta Health ServicesEdmonton, AB, Canada
Dr Roland AchmannGenteQHamburg, Germany
Prof. Thierry BienvenuInstitut CochinParis, France
Prof Karsten TiemannLaborKroneBad Salzuflen, Germany
CFTR Ion AmpliSeq™ Community panel
Goal: develop an NGS Panel for CFTR analysis
1. Complete coverage of 160 frequent CFTR variants (cftr2.org) Analyzes exons, intron-exon boundaries, and UTRs that contain common variants in the cystic
fibrosis transmembrane regulator (CFTR) gene. No mutation in the 3’ end of the primer Covers the common variants of the CFTR Gene as indicated by the CFTR2 database Detect Exon deletion to replace MLPA test – Feature nice to have
– Inclusive of 23 CFTR mutations recommended by the American College of Medical Genetics (ACMG)
• ~85% of Caucasian CF carriers
2. Use low amount of input DNA Works on DNA extracted from archived blood and Dried Blood Spot
3. Panel Verified by the global CFTR network on known samples: More than 300 archived research samples previously tested by CE sequencing Access to a very large sample database through the network
4. Adoptable by other research labs Reliable and easy data analysis. Ion Reporter ™ Software
Preliminary Results (146 samples)
Type Variants Detected Correct Genotype
Long HP 4/4 4/4Indel 82/82 82/82SNV 313/313 313/313
Sensitivity * 100 % 100 %
• Ion Reporter™ 1.6 analysis• CFTR Workflow with modified parameters for calling HP• A new workflow will be developed for a correct genotype calling
of a single difficult variant, not called automatically in IR 1.6
* Excluding difficult variant. Each position was considered as only one position, regardless of the number of samples at a particular position
Coverage Analysis For 2 Labs Preliminary results
Am
plic
on
Co
vera
ge
(lo
g10
)
Amplicons
• Final Panel design 102 amplicons• One Lab on Ion 314™ chip and the other lab on Ion 316™ chip • Up to 16 samples multiplexing is expected on Ion 314™ chip , 48 on Ion 316™
chip and 96 on Ion 318™ chip• Minimum 100x coverage – only one amplicon in one lab with low coverage but
this is run specific
1
10
100
1000
10000
100000
Lab1Lab2
Evaluation Metrics*
20.00%40.00%60.00%80.00%
100.00%
* Metrics have been calculated using 9 samples from one lab, GenteQ, ran in Life Tech laboratory in Darmstadt. These are preliminary results.
TP53 Ion AmpliSeq™ Community [email protected]
Goals1. Complete coverage of the TP53 Gene Coding regions
Analyzes exons, intron-exon boundaries.
2. Use low amount of input DNA Two primer pool requiring only 20 ng of DNA
3. Paraffin Embedded samples compatible Panel Verified on FFPE archived samples
4. Panel Verified by Prof Anne-Lise Borresen-Dale More than 30 archived research samples previously tested
by CE sequencing Access to a very large sample database through her network
5. Adoptable by other research labs Single day workflow Multiplex at least 8 samples per chip (Ion 316™ chip) Reliable and easy data analysis using Ion Reporter ™ Software
TP53 Ion AmpliSeq ™ Community Panel Final Panel Design
• 24 amplicons across 2 pools – 20 ng DNA• Compatible with DNA extracted by FFPE samples• 100% coverage of CDS• Recommended sample number to obtain 95% of amplicons at 500X
Coverage: 2 (Ion 314™ chip), 10 (Ion 316™ chip), 20 (Ion 318™ chip)
316 Chip: 10
TP53 Ion AmpliSeq™ Community Panel Ion Reporter ™ Software
• Panel has been tested on 30 Samples previously genotyped by CE:• 1 FN missed consistently due to complex mutation type and assembly• New algorithm will further improve sensitivity in the next software release
(~late Q3)
Type of Mutation Unique Positions Samples Genotyping Sensitivity
indel 9 8/9 88%
point mutations 11 11/11 100%
Overall sensitivity 95.00 %
First level: European expert network to develop AML gene panel– To propose list with significant targets– To test performance during design process by Ion Torrent‘s specialists– To verify panel on archived samples– To demonstrate complete workflow – Members:
• Prof. Christian Thiede, Dresden• Prof. Rosemary Gale, UCL• Prof. Claude Preudhomme, CHRU, Lille• Prof. Jacqueline Shoumans, CHUV
Lausanne
Second level: Extend network globally for panel review and feedback; project updates and early access option
AML Gene Panel [email protected]
Goal: Develop an NGS panel for AML genetic analysis
Markers in AML Core Panel: ASXL1, BRAF, CBL, CEBPA*, DNMT3A, FLT3, GATA2, IDH1,
IDH2, JAK2, KIT, KRAS, NPM1, NRAS, TPN11, RUNX1, TET2, TP53, WT1
Target list confirmed by numerous experts around the world
Design requirements/goals Hot spot on key variants and full exon coverage depending on the
targets Allele frequency detection 5% Two pool design
Panel development status Amplicon Design accepted and ready for synthesis (R&D)
*in bold = all exons covered
AML Ion AmpliSeq™ Community panel
Fast 1-day workflow
– Adoptable by other research labs
Reliable and easy data analysis using Ion Reporter™ Software
Panel Verified by the European AML network on archived samples
– Sequencing of 120+ mutated archived research samples (previously tested with other methods), plus 40 controls
– Access to a large sample database through the network
AML Ion AmpliSeq™ Community panel
• Ion lab: overall panel performancePhase 1:
Performanc and Coverage
• Ion lab: testing on archived clinical samples with selected variants
Phase 2:
Detection Sensitivity
• 4 network labs: 160 archived samplesPhase 3:
Analytical Sensitivity
CARDIO [email protected]
Dr Zofia MiedzybrodzkaNHS ScotlandAberdeen UK
Prof. Silvia PrioriFoundation Silvio MaugeriPavia, Italy
Prof Gilles MillatCHU LyonLyon, France
Dr Maria IasconeOspedali RiunitiBergamo, Italy
Dr Nicola MarzilianoOspedale NiguardaMilan, Italy
CARDIO Ion AmpliSeq™ Community Panel
Goal: develop a Pan CARDIO Gene Panel and a set of subpanels targeting genes involved in cardiomyopathy research
1. Selective gene content Gene content established by CARDIO Network collaborators. Decision to have one
Pan-CARDIO gene panel and 3 smaller, targeted subpanels (focused on main genes involved in cardiomyopathies, ARVC and channelopathies)
2. Pan CARDIO gene panel and subpanels to be validated by the CARDIO Network collaborators: Access to more than 2000 archived samples previously tested by other methods
3. Adoptable by other research labs Single day workflow Multiplex possible (depending on the subpanel) Reliable and easy data analysis . Complete workflow using Ion Reporter ™ Software
HLA typing is essential to match donor material with recipient for blood, bone marrow stem cell (leukemia) and organ transplantation
Transplantation - HLA typing
HLA Global [email protected]
Network consists of 16 Organizations:• 20 participants from Canada, US, Australia, Germany, Austria, Netherlands,
UK, France• registries, clinical research and research labs
Alpha test in July 2013 in Darmstadt lab- European participants: British Bone Marrow Registry University of Maastricht University of Vienna; EFI President University of Tuebingen
Goal: Develop NGS HLA high resolution assay on Ion Torrent™ PGM™ system including software solution
HLA Global Consortium
High resolution analysis:
6 classical full HLA genes
(class I: HLA-A,B,C and class II HLA-DRB, DQB, DPB)
Tiled Multiplex SR-PCR design; 400bp chemistry to minimize ambiguities
Software solution: HLA module Plugin software
HLA Global Consortium
Next Steps:
Now: availability HLA module plugin software v32 for Ion Suite- Evaluation and feedback
Q4 2013: - Beta testing with consortium members- ASHI Chicago Nov 17th workshop training
network meeting
Melanoma Research
New Panel Proposals
Colon Hereditary Research
Hearing loss
Research
?
??
Thyroid Cancer
Research
Circulating Tumor Cell Research
Minimal Residual Disease
Research
NEW!! User-shared panels on Ampliseq.com
We’ll be launching soon a new page on the Ampliseq.com website to promote panels developed and validated by Ion users.Submit yours now to [email protected] !
Frank
Astrid
Alexander
Rosella Annelore
SimoneNathalie
ChrysanthiMelanie
Alain
For Research Use Only. Not for use in diagnostic procedures.© 2013 Life Technologies Corporation. All rights reserved. The trademarks mentioned herein are
the property of Life Technologies Corporation and/or its affiliate(s) or their respective owners.
Start sequencing now atlifetechnologies.com/iontorrent
Thank you !
© 2013 Life Technologies Corporation. All rights reserved. The trademarks mentioned herein are the property of Life Technologies
Corporation and/or its affiliate(s) or their respective owners
For Research Use Only. Not for use in diagnostic procedures.Limitations and Disclaimer: Life Technologies Corporation takes no corporate position on the use of selection methods in IVF and prenatal settings though we acknowledge that people disagree about its appropriate use and it should ALWAYS be provided with full and informed, non-coerced prior informed consent.
The PGM™ System and equipment used herein is RUO marked and may not be GMP. The results shown may not represent actual performance in an IVF or any other setting. LTC does not assure or endorse the use of its methods in ANY clinical setting outside of those that have been reviewed by the FDA or similar oversight body.
Limitations and Disclaimers